Acute hepatitis C virus infection in incarcerated injection drug users

Standard

Acute hepatitis C virus infection in incarcerated injection drug users. / McGovern, Barbara H; Wurcel, Alysse; Kim, Arthur Y; Schulze zur Wiesch, Julian; Bica, Ioana; Zaman, M Tauheed; Timm, Joerg; Walker, Bruce D; Lauer, Georg M.

In: CLIN INFECT DIS, Vol. 42, No. 12, 15.06.2006, p. 1663-1670.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

McGovern, BH, Wurcel, A, Kim, AY, Schulze zur Wiesch, J, Bica, I, Zaman, MT, Timm, J, Walker, BD & Lauer, GM 2006, 'Acute hepatitis C virus infection in incarcerated injection drug users', CLIN INFECT DIS, vol. 42, no. 12, pp. 1663-1670. https://doi.org/10.1086/504327

APA

McGovern, B. H., Wurcel, A., Kim, A. Y., Schulze zur Wiesch, J., Bica, I., Zaman, M. T., Timm, J., Walker, B. D., & Lauer, G. M. (2006). Acute hepatitis C virus infection in incarcerated injection drug users. CLIN INFECT DIS, 42(12), 1663-1670. https://doi.org/10.1086/504327

Vancouver

Bibtex

@article{51faddb5b97849dc8fae93fc1e2099d6,
title = "Acute hepatitis C virus infection in incarcerated injection drug users",
abstract = "BACKGROUND: The Centers for Disease Control and Prevention has emphasized the need for interventional programs regarding hepatitis C virus (HCV) infection for injection drug users, the group of persons who are at highest risk of acquiring acute infection.METHODS: We designed a pilot study to assess the feasibility of identifying injection drug users with acute HCV infection in correctional and detoxification facilities. On-site medical providers were educated regarding risk factors and signs and symptoms of infection and were instructed to refer all patients with hepatitis to our specialty clinic.RESULTS: Over a 30-month period, 21 patients received a diagnosis of acute hepatitis C, 3 received a diagnosis of hepatitis B, and 1 received a diagnosis of hepatitis A. Of the 21 patients with acute hepatitis C, 19 were identified in the prison setting shortly after incarceration. Of the 17 patients who were observed serially (mean duration of observation, 6.3 months), 8 had spontaneous virologic clearance. Early therapy with pegylated interferon was initiated for 5 patients with persistent viremia and led to a sustained virologic response in 2 individuals. All patients agreed to undergo human immunodeficiency virus counseling and testing, as well as to receive immunization for hepatitis A and B.CONCLUSIONS: Incarceration presents a unique opportunity to identify injection drug users with acute HCV infection, to initiate counseling regarding other bloodborne pathogens, and to facilitate immunizations and HCV treatment.",
keywords = "Adult, Antiviral Agents/therapeutic use, Female, Hepacivirus/genetics, Hepatitis C/complications, Humans, Male, Middle Aged, Phylogeny, Pilot Projects, Prisoners/statistics & numerical data, RNA, Viral/blood, Substance Abuse, Intravenous/complications, Viral Load, Viremia",
author = "McGovern, {Barbara H} and Alysse Wurcel and Kim, {Arthur Y} and {Schulze zur Wiesch}, Julian and Ioana Bica and Zaman, {M Tauheed} and Joerg Timm and Walker, {Bruce D} and Lauer, {Georg M}",
year = "2006",
month = jun,
day = "15",
doi = "10.1086/504327",
language = "English",
volume = "42",
pages = "1663--1670",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Acute hepatitis C virus infection in incarcerated injection drug users

AU - McGovern, Barbara H

AU - Wurcel, Alysse

AU - Kim, Arthur Y

AU - Schulze zur Wiesch, Julian

AU - Bica, Ioana

AU - Zaman, M Tauheed

AU - Timm, Joerg

AU - Walker, Bruce D

AU - Lauer, Georg M

PY - 2006/6/15

Y1 - 2006/6/15

N2 - BACKGROUND: The Centers for Disease Control and Prevention has emphasized the need for interventional programs regarding hepatitis C virus (HCV) infection for injection drug users, the group of persons who are at highest risk of acquiring acute infection.METHODS: We designed a pilot study to assess the feasibility of identifying injection drug users with acute HCV infection in correctional and detoxification facilities. On-site medical providers were educated regarding risk factors and signs and symptoms of infection and were instructed to refer all patients with hepatitis to our specialty clinic.RESULTS: Over a 30-month period, 21 patients received a diagnosis of acute hepatitis C, 3 received a diagnosis of hepatitis B, and 1 received a diagnosis of hepatitis A. Of the 21 patients with acute hepatitis C, 19 were identified in the prison setting shortly after incarceration. Of the 17 patients who were observed serially (mean duration of observation, 6.3 months), 8 had spontaneous virologic clearance. Early therapy with pegylated interferon was initiated for 5 patients with persistent viremia and led to a sustained virologic response in 2 individuals. All patients agreed to undergo human immunodeficiency virus counseling and testing, as well as to receive immunization for hepatitis A and B.CONCLUSIONS: Incarceration presents a unique opportunity to identify injection drug users with acute HCV infection, to initiate counseling regarding other bloodborne pathogens, and to facilitate immunizations and HCV treatment.

AB - BACKGROUND: The Centers for Disease Control and Prevention has emphasized the need for interventional programs regarding hepatitis C virus (HCV) infection for injection drug users, the group of persons who are at highest risk of acquiring acute infection.METHODS: We designed a pilot study to assess the feasibility of identifying injection drug users with acute HCV infection in correctional and detoxification facilities. On-site medical providers were educated regarding risk factors and signs and symptoms of infection and were instructed to refer all patients with hepatitis to our specialty clinic.RESULTS: Over a 30-month period, 21 patients received a diagnosis of acute hepatitis C, 3 received a diagnosis of hepatitis B, and 1 received a diagnosis of hepatitis A. Of the 21 patients with acute hepatitis C, 19 were identified in the prison setting shortly after incarceration. Of the 17 patients who were observed serially (mean duration of observation, 6.3 months), 8 had spontaneous virologic clearance. Early therapy with pegylated interferon was initiated for 5 patients with persistent viremia and led to a sustained virologic response in 2 individuals. All patients agreed to undergo human immunodeficiency virus counseling and testing, as well as to receive immunization for hepatitis A and B.CONCLUSIONS: Incarceration presents a unique opportunity to identify injection drug users with acute HCV infection, to initiate counseling regarding other bloodborne pathogens, and to facilitate immunizations and HCV treatment.

KW - Adult

KW - Antiviral Agents/therapeutic use

KW - Female

KW - Hepacivirus/genetics

KW - Hepatitis C/complications

KW - Humans

KW - Male

KW - Middle Aged

KW - Phylogeny

KW - Pilot Projects

KW - Prisoners/statistics & numerical data

KW - RNA, Viral/blood

KW - Substance Abuse, Intravenous/complications

KW - Viral Load

KW - Viremia

U2 - 10.1086/504327

DO - 10.1086/504327

M3 - SCORING: Journal article

C2 - 16705568

VL - 42

SP - 1663

EP - 1670

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 12

ER -